Screener
SG&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Cost of revenue | — | 11 | — | 11 |
| Research and development | 135,283 | 97,509 | 244,205 | 216,154 |
| Selling, general and administrative | 30,196 | 22,283 | 53,535 | 46,227 |
| Restructuring, long-lived assets impairment and related charges, net | — | (172) | — | (182) |
| Total operating expenses | 165,479 | 119,631 | 297,740 | 262,210 |
| Income (loss) from operations | 73,467 | (118,417) | (58,823) | (257,964) |
| Other income: |
Item 1. Financial Statements (unaudited)
FAQ
- What is Vir Biotechnology, Inc.'s SG&A?
- Vir Biotechnology, Inc. (VIR) reported SG&A of $30.2M in Q2 2026.
- How has Vir Biotechnology, Inc.'s SG&A changed year-over-year?
- Vir Biotechnology, Inc.'s SG&A increased by 35.5% year-over-year, from $22.28M to $30.2M.
- What is the long-term trend for Vir Biotechnology, Inc.'s SG&A?
- Over 4 years (2021 to 2025), Vir Biotechnology, Inc.'s SG&A has grown at a -13.0% compound annual growth rate (CAGR), from $160.79M to $92.07M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Vir Biotechnology, Inc.'s sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude